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Cystatins are a family of naturally occurring cysteine
protease inhibitors, yet the target proteases and biological
processes they regulate are poorly understood. Cystatin F
is expressed selectively in immune cells and is the only
cystatin to be synthesised as an inactive disulphide-linked
dimeric precursor. Here, we show that a major target of
cystatin F in different immune cell types is the amino-
peptidase cathepsin C, which regulates the activation of
effector serine proteases in T cells, natural killer cells,
neutrophils and mast cells. Surprisingly, recombinant
cystatin F was unable to inhibit cathepsin C in vitro even
though overexpression of cystatin F suppressed cellular
cathepsin C activity. We predicted, using structural mod-
els, that an N-terminal processing event would be neces-
sary before cystatin F can engage cathepsin C and we show
that the intracellular form of cystatin F indeed has a
precise N-terminal truncation that creates a cathepsin C
inhibitor. Thus, cystatin F is a latent protease inhibitor
itself regulated by proteolysis in the endocytic pathway. By
targeting cathepsin C, it may regulate diverse immune cell
effector functions.
The EMBO Journal (2008) 27, 499–508. doi:10.1038/
sj.emboj.7601979
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Introduction
The cystatins are naturally occurring cysteine protease in-
hibitors found either within the cytosol or secreted from cells
(Abrahamson et al, 2003; Kopitar-Jerala, 2006). In humans,
there are currently 11 family members divided into three
subgroups depending on the presence of single or multiple
‘cystatin’ domains and the presence or absence of a signal
sequence. Cystatins are potent inhibitors of the C1 family
of cysteine proteases and some members of the type II
subgroup also inhibit the C13 family protease asparaginyl
endopeptidase (AEP)/legumain (Alvarez-Fernandez et al,
1999; Manoury et al, 2001). The C1 cysteine proteases include
the endosomal/lysosomal cathepsins, which are involved in
many key biological processes such as bone remodelling as
well as development and function of the immune system.
These enzymes have also been linked to tumour cell invasion
(Jedeszko and Sloane, 2004) and to arterial remodelling and
atherogenesis (Liu et al, 2004), implying that their regulation
is important. In principle, cystatins can provide this regula-
tion but the physiological situations in which they do so are
not clear. The importance of cystatins is underlined by
pathological conditions that arise upon loss or mutation of
some cystatin genes. For example, mice lacking cystatin
M exhibit abnormal and eventually lethal defects in the
development of the epidermis (Zeeuwen et al, 2002).
Several cystatin structures have now been solved, two in
complex with proteases. These structures reveal the ‘cystatin
fold’, a ﬁve-stranded b-sheet wrapped around an extended
helix and a protease-interacting ‘edge’ made up of the
N-terminal region and two loops found at the end of the
antiparallel b-sheet (Bode et al, 1988; Stubbs et al, 1990; Jenko
et al, 2003). Inhibition of AEP is due to a second distinct
protease-binding site (Alvarez-Fernandez et al, 1999). Although
some cystatins are partially localised within the vacuolar
system of mammalian cells, type II cystatins are primarily
secreted into the external milieu where they are proposed to
‘mop up’ potentially harmful cysteine proteases released from
cells (Abrahamson et al, 2003; Kopitar-Jerala, 2006).
Cystatin F is a type II cystatin whose expression is limited
primarily to cells of the immune system such as T cells,
natural killer (NK) cells and dendritic cells (Halfon et al,
1998; Ni et al, 1998; Hashimoto et al, 2000; Obata-Onai et al,
2002). Cystatin F was identiﬁed as one of the most up-
regulated transcripts in monocyte-derived dendritic cells
undergoing LPS-induced maturation (Hashimoto et al, 2000)
and was independently identiﬁed as CMAP (cystatin-like
metastasis associated protein) whose level of expression
correlated with metastatic potential in liver tumours
(Morita et al, 1999). Cystatin F has relatively low sequence
homology to other family members (B35%), the main
distinguishing features being an extended N-terminal region,
two additional cysteine residues and non-conservative sub-
stitutions in the putative protease-interacting domains.
Cystatin F was shown to be secreted as a disulphide-linked
dimer (Cappello et al, 2004), which is inactive until it is
reduced to its monomeric form (Langerholc et al, 2005). This
form was shown to inhibit cathepsins L, V, K and F most
potently, while cathepsins S and H were less sensitive and
cathepsins B and C were not inhibited (Halfon et al, 1998;
Ni et al, 1998; Langerholc et al, 2005). Received: 2 July 2007; accepted: 12 December 2007
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499We recently described the crystal structure of human
cystatin F. Its dimeric form is stabilised by two inter-subunit
disulphide bridges between Cys26 in the extended N termi-
nus of one monomer and Cys63 on the other monomer
(Schuettelkopf et al, 2006). The resulting dimer is unable to
bind to C1 family cysteine proteases, due to mutual steric
hindrance of the protease-binding sites. Cystatin F is the only
cystatin to be made as an inactive precursor, indicating that
its activity can be regulated and suggesting an intracellular
function. Indeed, compared with cystatin C, a much larger
fraction of cystatin F in U937 cells is directed to intracellular
compartments (Nathanson et al, 2002).
We reasoned that the target proteases and potential func-
tions of cystatin F in immune cells might be elucidated by
isolation of endogenous cystatin F–protease complexes.
Surprisingly, given earlier data that cathepsin C could not
be inhibited by cystatin F (Langerholc et al, 2005), we show
that this enzyme is one of its principal interacting partners.
We resolve this anomaly by showing that cystatin F must
undergo an N-terminal processing event to acquire cathepsin
C inhibitory capacity. Since cathepsin C/DPPI is essential for
the activation of a range of granule-localised serine proteases
in Tcells, NK cells, neutrophils and mast cells, cystatin F may
have an important regulatory role in immune cells.
Results
Cystatin F expression in immune cells
To study cystatin F, we expressed it using a vector that
permitted substantial amounts to be secreted from CHO
cells (Li et al, 2003). As expected the puriﬁed protein was a
disulphide-linked dimer and showed several distinct forms
due to heterogeneous N-linked glycosylation (Figure 1A, left;
Ni et al, 1998; Nathanson et al, 2002; Cappello et al, 2004).
Site-directed mutagenesis of either Cys26 or Cys63 prevented
dimer formation, conﬁrming that inter-subunit disulphide
bridges involved these residues (Schuettelkopf et al, 2006;
Figure 1A, right). As recently shown by others (Langerholc
et al, 2005), inhibitory activity against cathepsin L was only
revealed following incubation with millimolar levels of redu-
cing agents (Figure 1B). Cystatin F was expressed primarily in
CD8
þ T cells and in CD56
þ NK cells consistent with mRNA
data (Halfon et al, 1998; Obata-Onai et al, 2002) and while
most appeared to be monomeric a signiﬁcant amount of
inactive dimer was also present (Figure 1C). Lower levels
of cystatin F were observed in CD16
þ cells but expression
was not detected in CD4
þ Tcells, CD19
þ B cells or in resting
CD14
þ monocytes. However, cystatin F expression was
detected as monocytes differentiated into dendritic cells and
consistent with the SAGE analysis of Hashimoto et al (2000),
dendritic cell maturation with TLR ligands further increased
cystatin F expression (Figure 1D).
Cystatin F is complexed with cathepsin C in immune
cells
To identify protease targets of cystatin F, we isolated cystatin
F from detergent lysates of the human monocytic and NK cell
lines U937 and YT. Parallel lysates were mixed with
Sepharose beads carrying either afﬁnity-puriﬁed anti-cystatin
Fantibodies or control rabbit IgG. Bound proteins were eluted
and separated by SDS–PAGE. As shown in Figure 2A, several
species were speciﬁcally recovered in the anti-cystatin F
precipitates. MALDI TOF/TOF mass ﬁngerprinting identiﬁed
cystatin F itself and a smaller protein with apparent mol. wt.
B7kDa that was consistently observed in both U937 and YT
samples (bands 3 and 5 in Figure 2A). This protein was
identiﬁed as the light chain of cathepsin C (Supplementary
Figure S1). The heavy chain of cathepsin C was also identiﬁed
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Figure 1 Cystatin F production and endogenous expression in immune cells. (A) Left panel: puriﬁed recombinant cystatin F is a disulphide-
linked dimer with heterogeneous N-linked glycosylation. Right panel: mutagenesis of either Cys26 or Cys63 prevents dimer formation in
transiently transfected 293Tcells. (B) Cathepsin L inhibitory activity appears upon dimer reduction. (C) Cystatin F is expressed principally in
human CD8
þ T cells and in CD56
þ cells, which are predominantly NK cells. In addition to dimer and monomer, an additional species (*)
is seen in U937. Equal protein was loaded for all cells. (D) Cystatin F is induced as CD14
þ monocytes differentiate into dendritic cells and is
further induced by stimulation with TLR4 (LPS) or TLR3 (poly I:C) ligands. All gels were non-reducing except (D).
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U937 cells (Figure 2A, band 1 and Supplementary Figure S1).
Although some other cysteine proteases were also identiﬁed,
we were intrigued by the association with cathepsin C, which
was reported to be resistant to inhibition by recombinant
cystatin F (Langerholc et al, 2005).
Cystatin F fails to inhibit cathepsin C in vitro but
suppresses its activity in vivo
We reinvestigated the capacity of cystatin F to inhibit cathe-
psin C in vitro. Consistent with the study of Langerholc et al
(2005), reduction of cystatin Fallowed inhibition of cathepsin
L but not cathepsin C (Figure 2B). To investigate why cystatin
Fassociates with cathepsin C in living cells yet cannot inhibit
the enzyme in vitro, we asked whether cystatin F can inhibit
cathepsin C in vivo. 293T cells were transfected with either
cystatin F, cystatin C or control vector and 48h later the
activity of cathepsins L and C was measured in cell lysates
using appropriate substrates. Transfection with cystatin F
suppressed the activity of endogenous cathepsins L and C,
as did cystatin C (Figure 2C), albeit less potently presumably
because a greater fraction is secreted (Nathanson et al,
2002). Cystatin F also inhibited overexpressed cathepsin C
(Figure 2D). Cystatin F might suppress cathepsin C activity
directly or indirectly since, unlike most C1 cysteine proteases,
cathepsin C does not autoactivate but rather is activated by
other proteases (Dahl et al, 2001; Mallen-St Clair et al, 2006).
We tested the possibility that cystatin F might suppress
cathepsin C activation by transfecting cystatin F, cathepsin
C or control vector DNA into separate populations of 293T
cells and then mixing the lysates in different ratios before
measuring cathepsin C activity. However, consistent with
direct inhibition of activated cathepsin C, lysates from cysta-
tin F-transfected cells were able to suppress cathepsin C
activity in parallel cell lysates (Figure 2E). Inhibition was
not complete, presumably because of the large dilution of
inhibitor and target protease in the cell lysates.
The N terminus of cystatin F cannot be accommodated
in the active site of cathepsin C
The above results presented a paradox. Cystatin F suppressed
cathepsin C activity following expression in 293T cells
and interacted with cathepsin C in U937, YT and 293T cells
(Figure 2 and data not shown), yet recombinant monomeric
cystatin F was inactive in vitro as a cathepsin C inhibitor. To
try to resolve this discrepancy, we generated model structures
for complexes between cystatin F and cathepsin C as well as
other C1 cysteine proteases using the existing co-crystal
structures of papain and steﬁn B (Stubbs et al, 1990),
cathepsin H and steﬁn A (Jenko et al, 2003) and cathepsin
C (Turk et al, 2001) as templates. In cystatin C and chicken
egg white cystatin, the N-terminal region is an important
determinant of the afﬁnity of the inhibitor for its target
proteases (Abrahamson et al, 1991; Lindahl et al, 1992).
Modelling experiments showed that the extended N terminus
of cystatin F could be accommodated in the cathepsin L
active site, and in the active sites of other C1 family
endopeptidases through placement over the non-prime
subsites (S2, S3, S4, etc.) in an analogous manner to that
proposed for cystatin C (Bode et al, 1990). However, this is
not possible in the case of cathepsin C because the exclusion
domain closes the substrate channel beyond the S2 subsite
(Turk et al, 2001). As shown in Figure 3A, the cystatin F
N-terminal region might fold back in a hook-like conformation
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Figure 2 Cystatin F is associated with cathepsin C in U937 and YTcells and inhibits its activity in vivo but not in vitro.( A) Proteins associated
with anti-cystatin F or control antibodies were isolated from U937 and YT cells and separated by reducing SDS–PAGE. The numbered bands
were excised and identiﬁed by tryptic mass ﬁngerprinting as cathepsin C heavy chain/cystatin F (band 1), cystatin F (bands 2 and 4) and
cathepsin C light chain (bands 3 and 5). Tryptic peptide coverage and peptides conﬁrmed by MS/MS sequencing are shown in Supplementary
Figure S1. (B) Cystatin F monomer generated with DTT inhibits cathepsin L (closed circles) but not cathepsin C (open circles). (C) Cystatin F
inhibits cathepsin C activity in living cells; 293Tcells were transfected with pcDNA3.1 DNA (empty vector control) or pcDNA3.1 into which
either cystatin C or F had been cloned. After 48h, post-nuclear cell lysates were tested for cathepsin L or cathepsin C activity. (D) As in (C)
except cathepsin C was additionally expressed in 293Tcells with or without cystatin C or F. (E) Lysates of 293Tcells separately transfected with
cystatin For control empty vector were mixed with lysates from cathepsin C-transfected cells. The ratio of cystatin F lysate to control lysate was
varied as shown and cathepsin C activity assayed as before.
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aminopeptidase, cathepsin H (Jenko et al, 2003), but this is
unlikely as such a conformation would bring the bulky
side chain of Phe38 in cystatin F (Gly in steﬁn A) in close
proximity with other residues, in particular Lys35. However,
truncation of the cystatin F N terminus would allow it to be
accommodated in the cathepsin C active site (Figure 3B).
Moreover, truncation to Lys 35 might permit a favourable
interaction between the Lys side chain and the chloride ion at
the bottom of the S2 pocket (Figure 3C). Truncation to this
point, but not beyond would align the N terminus of cystatin
F with the residues known to contribute most to the binding
of the N-terminal region of cystatin C to target proteases
(Abrahamson et al, 1991; Figure 3D).
The cellular form of cystatin F is truncated to Lys35 to
permit cathepsin C inhibition
To test the prediction that cellular cystatin F undergoes
N-terminal processing, we isolated cystatin F from U937 cells,
separated the dimeric and monomeric forms by non-reducing
SDS–PAGE and subjected them to N-terminal sequence ana-
lysis. As shown previously, U937 cells contain a mixture of
dimeric inactive cystatin F and monomeric ‘active’ protein
(Nathanson et al, 2002; Langerholc et al, 2005; Figure 1). The
dimeric form had the same N-terminal sequence (GPSPD) as
secreted cystatin F, indicating that signal sequence cleavage
but no further processing had occurred. Interestingly, the
sequence of the monomeric form was truncated by 15
residues to lysine 35 (KPGF), exactly as suggested by the
modelling analysis (Figure 4A). As expected, other bands
corresponded to cathepsin C sequences (Figure 4A). We
generated a new recombinant form of cystatin F lacking the
ﬁrst 15 residues (D15N cystatin F), which was secreted in
monomeric form since it lacks Cys26 (Supplementary Figure
S2). Crucially, whereas full-length monomeric cystatin F
inhibited cathepsin C poorly, even at high concentrations
(IC5041mM), D15N cystatin F was an effective cathepsin C
inhibitor with an IC50 value of 3474nM (Figure 4B). In
contrast, both full-length and truncated cystatin F were
potent inhibitors of cathepsin L (Figure 4C), although the
truncated form demonstrated a somewhat lower afﬁnity for
cathepsin L compared to the full-length inhibitor
(IC50¼120720 versus 3976pM), indicating that residues
N-terminal of Lys35 contribute to cystatin F binding to
cathepsin L.
Thus, cystatin F only becomes a cathepsin C inhibitor
following an intracellular processing event that removes the
sterically hindering N terminus. To demonstrate that cystatin
F is similarly processed in primary immune cells, we devel-
oped an antibody (N1) speciﬁc for the processed 15-residue
N-terminal sequence. Indeed, we found that in human
CD56
þ NK cells and CD8
þ T cells the N1 antibody reacted
with inactive dimeric but not with monomeric cystatin F
(Figure 4D). Metabolic pulse-chase labelling of U937 cells
demonstrated that cystatin F monomer is only observed after
2–4h of chase as the dimeric form disappears (Figure 4E).
Further, while some dimer and a form migrating between
dimer and monomer were secreted into the medium, the
monomer was only found in cell lysates, consistent with
conversion after leaving the secretory pathway (Figure 4E).
The intermediate species (asterisks in Figure 4D and E) has
been seen previously in U937 cells (Nathanson et al, 2002;
Cappello et al, 2004). Its slower migration appears to be due
to unusual glycosylation of the monomeric form since it is
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Figure 3 (A) Theoretical model of the interaction of full-length cystatin F (blue) with cathepsin C (grey/red) showing the clash between the
extended N terminus of cystatin F and the exclusion domain of cathepsin C. (B) Truncation of cystatin F by 15 residues removes this steric
hindrance and may allow the now N-terminal Lys35 to interact with the chloride ion (green) at the bottom of the cathepsin C S2 subsite.
(C) Details of the proposed interaction between truncated cystatin F and the cathepsin C S2 subsite. Possible hydrogen bonds between the
amino groups of Lys35 and cathepsin C, as well as the contact between Lys35 and the chloride bound at the bottom of the S2 subsite are
indicated with dotted lines. Key residues are labelled and coloured according to parent chain. (D) The N-terminal sequences of cystatin F and
cystatin C are aligned and amino-acid identities are coloured in blue. The 15 amino acids removed by cleavage (arrow) in cystatin Fare in grey.
Cys26 participating in dimer formation in cystatin F is starred and secondary structure elements (red¼a-helix, blue¼b-strand) are marked
above the sequence. In cystatin C, the key Leu-Val-Gly sequence for interaction with C1 cysteine protease S3-S1 non-prime sites (Bode et al,
1990) is underlined.
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antibody and upon Endo H treatment, migrates similar to
monomer (Supplementary Figure S3). Further characterisa-
tion of this species is needed to establish its glycosylation
status and its ability to dimerise.
Cystatin F is activated following targeting to the
endocytic pathway
To examine the cellular localisation of dimeric and mono-
meric cystatin F in more detail, we disrupted U937 cells and
fractionated post-nuclear supernatants on Percoll gradients.
The dimeric and monomeric forms of cystatin F showed a
strikingly distinct distribution. Whereas dimeric cystatin F co-
migrated with markers of the ER (PDI) and Golgi apparatus
(TGN46), monomeric cystatin F co-migrated with the bulk of
b-hexosaminidase activity, consistent with lysosomal locali-
sation (Figure 5A). Moreover, the latter form reacted with the
antibody raised against whole cystatin F (CF) but not with the
N1 antibody conﬁrming N-terminal processing (Figure 5A).
The distribution of processed and unprocessed cystatin F was
also distinct in primary murine bone marrow-derived mast
cells (BMMCs). In cells that expressed both cystatin F and
cathepsin C, intact cystatin F, detected with the N1 antibody,
was seen in many small structures some of which were
positive for the Golgi marker GM130, but did not colocalise
with cathepsin C (Figure 5B and Supplementary Figure S4A).
In contrast, the CFantisera reactive with intact and processed
cystatin F labelled many, though not all, cathepsin C-positive
structures (Figure 5B). Cystatin F also partially colocalised
with the cathepsin C substrate, granzyme A as well as
with perforin and LAMP1 in human CD8
þ T-cell blasts
(Supplementary Figure S4B). Importantly, we could conﬁrm
colocalisation of cystatin F and granzyme A at the ultrastruc-
tural level in human CD8 T-cell granules (Figure 5C). Taken
together, these data demonstrate conversion of dimeric to
monomeric cystatin F within the endocytic pathway.
Moreover, the monomeric cystatin F in dense lysosomal
vesicles and those harbouring cathepsin C in murine mast
cells appeared to be processed to the truncated active form.
Cystatin F and cathepsin C function in immune cells
To assess directly the consequences of manipulating cystatin
F levels in immune cells, we expanded primary murine Tcells
and mast cells from spleens and bone marrow, respectively,
and transduced the cells with a bicistronic GFP-containing
retroviral vector that expressed either murine wild-type
cystatin F or an N-terminally truncated version analogous
to the form we found in U937 cells. GFP-positive cells were sorted
by FACS and cathepsin C activity was measured in cell
lysates. Cathepsin C activity was signiﬁcantly suppressed
by cystatin F overexpression in both CD8
þ T cells and mast
cells (Figure 6A). In mast cells (BMMC), we also measured
levels of chymase-dependent chloroacetate esterase (CAE)
activity, which was reported to be completely lacking in
cathepsin C-null mast cells (Wolters et al, 2001). As shown
in Figure 6B and C, compared with mast cells expressing GFP
alone, CAE activity was substantially suppressed by retroviral
expression of cystatin F and even more so by expression of
the N-terminally truncated form in spite of the fact that it was
expressed at a reduced level compared with the full-length
protein (Supplementary Figure S4). Taken together, these
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cathepsin C activity in primary immune cells.
Discussion
Cystatins have generally been thought of as ‘housekeeping’
genes whose role is to inhibit inadvertently released cysteine
proteases before they can cause tissue damage. In the case of
cystatin F, recent data challenge this view by showing that the
secreted form of cystatin F is a functionally inactive disul-
phide-linked dimer (Langerholc et al, 2005; Schuettelkopf
et al, 2006; Figure 1B). Instead, its domain of action is likely
to be within the endocytic pathway and consistent with this,
a much greater proportion of cystatin F is retained in cells
compared with other ‘secreted’ cystatins such as cystatin C
(Nathanson et al, 2002). Its restricted expression in immune
cells (Ni et al, 1998) and some tumours (Morita et al, 1999)
suggests that it might have important regulatory functions,
making it imperative that its physiological protease targets
are identiﬁed. We show here that cathepsin C is a physiolo-
gical target of cystatin F but only once cystatin F has under-
gone post-translational proteolytic processing. Processing
confers a ‘gain of function’ on cystatin F and sets it apart
from other family members such as cystatin C where trunca-
tion of its N terminus dramatically reduced its inhibitory
activity against cathepsins B and L (Abrahamson et al, 1991).
Cathepsin C activates several important serine protease
zymogens in T cells, NK cells, neutrophils and mast cells,
including the granzymes A and B, cathepsin G, elastase,
proteinase 3 and mast cell chymase. Activation is achieved
by removal of an ‘activation dipeptide’ at the N terminus
(Salvesen and Enghild, 1990). The importance of cathepsin C
in immunobiology is underlined by the phenotype of cathe-
psin C-deﬁcient mice, which accumulate the zymogen forms
of the above-mentioned substrates and fail to activate neu-
trophil serine proteases (Adkison et al, 2002) and mast cell
chymase (Wolters et al, 2001). Defective cytotoxic T-cell
effector function has also been reported in some studies
(Pham and Ley, 1999) though not in others (Sutton et al,
2007). In humans, Papillon–Lefe `vre syndrome occurs
as a result of mutations in the cathepsin C gene and
affected individuals exhibit periodontitis, skin infections and
other abnormalities. Defects in resting NK cell function
in Papillon-Lefe `vre patients have also been found and
attributed to failure to activate granzyme B (Meade
et al, 2006). While cathepsin C is clearly crucial, there
is also evidence that attenuation of its activity may be
beneﬁcial. Cathepsin C-deﬁcient mice were protected from
acute inﬂammatory arthritis due to attenuated neutrophil
recruitment in the affected joints, which in turn is due to
lack of elastase and cathepsin G activity (Adkison et al, 2002)
and were more resistant in an aortic inﬂammation model
likely driven by cathepsin C-dependent neutrophil serine
proteases (Pagano et al, 2007). Cathepsin C-null mice
were also more resistant to sepsis due to an altered mast
cell-driven inﬂammatory response (Mallen-St Clair et al,
2004). On the basis of these and other data, cathepsin C
has been proposed as a drug target for control of inﬂamma-
tion. Our data suggest that cystatin F may be an important
endogenous cathepsin C regulator.
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Figure 5 Dimeric and processed monomeric cystatin F are found in distinct cellular compartments. (A) Non-reducing SDS–PAGE analysis of
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fractions compared with dimeric cystatin F (detected with Abs CFand N1). ER (PDI), Golgi (TGN46) and lysosome (b-hexosaminidase) marker
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cathepsin C can be understood in the context of the structures
of cystatin–C1 cysteine protease complexes. All members of
the C1 cysteine protease family have a common fold which,
in the case of exopeptidases, is supplemented by additional
domains that block parts of the active site. In the case of
cathepsins C and H, access of the substrate beyond the S2
pocket is blocked by occluding domains not found in the
endopeptidases, and these structural features determine the
aminopeptidase activity of these proteases (Guncar et al,
1998; Turk et al, 2001). These domains also present a
potential barrier to the docking of cystatins, which orient in
the active site channel with their N-terminal region lying in
and beyond the S2 pocket. In the cathepsin H/steﬁn A
structure, the N-terminal region of steﬁn A is accommodated
by adopting a hook-like structure, which partially displaces
the mini-chain (Jenko et al, 2003). However, the cystatin F N
terminus is 14 residues longer than that of steﬁn A and
substitution of bulky residues at key places (e.g. Phe38
for Gly found in most other cystatins) may prevent a
similar arrangement. Thus, full-length cystatin F can inhibit
endopeptidases such as cathepsin L, which can presumably
accommodate the N-terminal extension along the open sub-
strate channel, but not aminopeptidases such as cathepsin C.
We speculate that the positively charged terminal lysine of
truncated cystatin F interacts with the chloride ion located at
the bottom of the S2 pocket (Turk et al, 2001; Molgaard et al,
2007). The N terminus of truncated cystatin F (KPGF) is
evidently a poor substrate of cathepsin C, but apparently,
together with the two loop domains, a good inhibitor, a
ﬁnding supported by the fact that substrates with a lysine
in the P2 position are not only not cleaved, but in fact
are themselves competitive inhibitors of cathepsin C
(Tran et al, 2002).
Our results suggest an alternative pathway for the
activation of cystatin F in living cells involving proteolysis
instead of disulphide bond reduction (Figure 7). Proteolytic
cleavage at any of the residues between Cys26 and Lys35
would break the covalent linkage and hence the mutual steric
hindrance between the dimer subunits. Protease binding, at
least to some targets, could then occur since the short
N-terminal peptide generated would be disulphide linked to
Cys63 of the other subunit, well away from the protease-
binding interface (Schuettelkopf et al, 2006; Figure 7). Given
the high levels of reducing agent needed to activate cystatin
F (Langerholc et al, 2005; Figure 1) and our ﬁnding
that monomeric cystatin F had a processed N terminus
(Figures 4 and 5), proteolysis might be the dominant mode
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enzyme(s) that generate the processed intracellular form of
cystatin F. An intriguing possibility is that cathepsin C itself
and/or its downstream protease substrates might be involved
in this activation step, providing a novel mechanism to
‘self-limit’ the activity of these protease systems.
The striking coincidence of cystatin F expression in cells
harbouring cathepsin C-activated granule proteases is con-
sistent with the idea that cystatin F may attenuate this
protease system. For example, in human peripheral blood,
high levels of cystatin F were found in CD8
þ T cells and
NK cells, whereas lymphocytes whose functions do not
depend on exocytosis of granule-localised effector serine
proteases, such as CD4 T cells and B cells, did not express
cystatin F (Figure 1). Cystatin F was also expressed in
monocyte-derived dendritic cells (Figure 1; Hashimoto et al,
2000) as is cathepsin C (Hashimoto et al, 1999; Le Naour
et al, 2001) To our knowledge, the function of cathepsin C in
dendritic cells is not known. Conceivably, this is related to
the recent demonstration that activated DCs have tumoricidal
activity and express perforin and granzyme B (Stary
et al, 2007).
Cystatin F colocalised with cathepsin C in murine mast
cells and with the cathepsin C substrate granzyme A in
human CD8 T cells. Overexpression of cystatin F in both
mast cells and CD8
þ Tcells suppressed cathepsin C activity.
However, there were clearly cystatin F-positive organelles
within mast cells and CD8 T cells that lacked cathepsin
C and/or its downstream substrates, and vice versa. This
implies that cystatin F access to the granule system and by
implication its capacity to downregulate cathepsin C activity,
may be additionally regulated by inter-compartmental fusion
events. In U937 cells, Langerholc et al (2005) showed cystatin
F colocalises with cathepsins H and X but not with cathepsin
L and other enzymes inhibited by cystatin F in vitro. Cystatin
F/cathepsin colocalisation studies need to be interpreted with
caution bearing in mind that cystatin F visualised by micro-
scopy may not necessarily be in an active conﬁguration and
conversely, low amounts of active cystatin F may be difﬁcult
to visualise, but may nonetheless be functionally signiﬁcant.
An earlier study concluded that cystatin F did not accumulate
in the endocytic pathway of U937 cells, although, consistent
with our results, a dimeric form was detected in low-density
Percoll gradient fractions and in the medium (Cappello et al,
2004). This apparent discrepancy can be readily explained by
the fact that the antibody Cappello and colleagues used was
raised against the N terminus of cystatin F, which as we show
is removed by endosomal processing. Consistent with this
interpretation and with our hypothesis that proteolysis is the
dominant mode of activation, Cappello et al (2004) did
not detect monomeric cystatin F in U937 cell lysates under
non-reducing conditions.
In summary, by isolating an unusual cystatin from the
speciﬁc cell types in which it is expressed, we have discov-
ered an unexpected protease target. As an endogenous in-
hibitor of cathepsin C, cystatin F may attenuate the activation
of a wide range of downstream serine proteases involved in
inﬂammation and immunity. Access to the cathepsin C active
site is regulated by proteolytic processing and perhaps by as
yet undeﬁned protein/membrane trafﬁcking events. Deﬁning
how cells regulate cystatin F activation and cathepsin C
interactions will be a key next step.
Materials and methods
Cell culture and isolation
Cell lines were cultured in RPMI 1640 (U937, YT, BMMC and CD8
þ
T cells) or DMEM (293T)-based media. DHFR-negative CHO cells
were grown in IMDM-based media containing 0.1mM hypox-
anthine and 0.01mM thymidine (HT). Following transfection with
DHFR plasmids, the HTsupplement was removed and methotrexate
added at 0.1–10mM, depending on the stage of selection (see
Supplementary data). Mast cells and CD8
þ T cells were cultured
from the bone marrow and spleen, respectively, of C57Bl/6 mice.
Mast cells were expanded over 4–8 weeks in media supplemented
with IL-3 (10% WEHI-conditioned medium) as described (Razin
et al, 1984) and purity checked by FACS analysis for Fce-RI and
CD117 (c-Kit) (Supplementary Figure S5). CD8
þ T cells were
expanded from splenocytes by stimulation with 0.5mg/ml anti-
CD3e (BD Bioscience) in the presence of 20ng/ml recombinant
human IL-2 (Chiron). Human ‘buffycoats’ (Ninewells Hospital,
Dundee) were used to isolate monocytic cells on Ficoll Paque
(Amersham Biosciences) and B cells, CD4
þ T cells, CD8
þ T cells,
monocytes, neutrophils and NK cells were isolated by positive
selection using anti-CD19, -CD4, -CD8, -CD14, -CD16 and -CD56
magnetic beads (Miltenyi), respectively, and purity was checked by
FACS staining using PE-conjugated antibodies directed against the
same cell surface markers except anti-CD20 was used to assess
B-cell purity. Dendritic cells were differentiated from CD14
þ
monocytes in GMCSF (800U/ml; Leucomax, Sandoz) and IL-4
(1000U/ml; BD Biosciences) essentially as described by Sallusto
and Lanzavecchia (1994). DC maturation was induced with 1mg/ml
LPS and conﬁrmed by FACS-monitored increase in CD40 and CD83.
Plasmids, transfections and retroviral transduction
Human cystatin F, additionally encoding a 6-histidine C-terminal
tag, was ampliﬁed from cDNA as detailed in Supplementary data.
Cystatin F with a deletion of 15 amino acids downstream of the
signal sequence (D15N cystatin F) was generated by separate
ampliﬁcation of the signal sequence and residues 35–145 of cystatin
F and subsequent fusion of the two PCR products. Cathepsin C and
cystatin C sequences were ampliﬁed from U937 cDNA and cloned
into vectors pCMV4a and pcDNA3.1, respectively. Mutagenesis of
Cys26 and Cys63 of wild-type cystatin F cloned into pcDNA3.1 was
performed using the QuikChange site-directed mutagenesis kit
(Stratagene). Murine cystatin F was isolated from cDNA generated
from CD8
þ T cells and cloned into the BamHI and NotI sites of
retroviral vector LZRS-pBMN (gift of Dr Gary Nolan). Full methods
and all primer sequences can be found in Supplementary data.
293T cells (1 10
6 cells/10cm dish) were transfected with 2mg
DNA using 8ml Fugene reagent (Roche) in a ﬁnal volume of
100 ml serum-free medium. DNAs for co-transfection (pCMV and
pcDNA3.1 constructs) were mixed in a 1:2 ratio. Cells were
analysed 48h later. Retrovirus was produced in the packaging cell
line Phoenix Eco 293T as described previously (West et al, 2004)
and concentrated 10-fold. Primary spleen and bone marrow cells
were transduced by ‘spinfection’ (2000r.p.m., 60min, 251C) and
GFP-expressing cells were sorted by FACS on day 3 (CD8
þ Tcells)
or week 4 (mast cells). Cystatin F expression was conﬁrmed by
western blot.
Cystatin F isolation and antibody production
Recombinant 6-His-tagged cystatin F or D15N cystatin F was
expressed using a gene ampliﬁcation protocol described previously
(Li et al, 2003). Brieﬂy, CHO DHFR-negative cells were transfected
with the 6-His cystatin F pcDNA-DHFR plasmid and selected for
growth in medium lacking HT supplement. Supernatants were
initially screened by western blot using an anti-cystatin F antibody
kindly provided by Dr M Abrahamson and positive clones were
selected for increased cystatin F production by culture in increasing
concentrations of methotrexate (0.1–10mM) over several weeks.
Cystatin F was puriﬁed from the culture medium by sequential
puriﬁcation on Ni-NTA agarose (Qiagen), Sephacryl S200 and Hi-
Trap SP XL cation exchange resin as detailed in Supplementary data.
The ﬁnal yield of protein was approximately 8mg/l of culture
medium. Antibodies were raised in rabbits (Diagnostics Scotland)
against either whole human or mouse cystatin F or against the N-
terminal sequences GPSPDTCSQDLNSRV (human) or ARPPDFCSK-
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to KLH.
Isolation of cystatin F–protease complexes
Cystatin F and associated proteins were isolated from detergent
lysates of U937 and YT cells using afﬁnity-puriﬁed rabbit anti-
cystatin F antibodies or control rabbit Ig coupled to Sepharose.
Proteins were eluted from the washed adsorbent and separated on
4–12% Bis–Tris Novex pre-cast SDS–PAGE gels. Proteins speciﬁcally
precipitated by anti-cystatin F antibodies were excised, digested
with trypsin and analysed by mass spectrometry. Sequence analysis
of dimeric and monomeric cellular cystatin F utilised a similar
procedure except that a total membrane fraction was generated
following mechanical disruption of U937 cells. Following detergent
solubilisation, cystatin F was immunoprecipitated and separated by
non-reducing SDS–PAGE. N-terminal sequence analysis was per-
formed by Edman degradation. Detailed methods can be found in
Supplementary data.
Protease assays
All assays were performed on a FLUOstar Optima Fluorimeter
(BMG) with 360nm excitation and 460nm emission wavelength
ﬁlters. Recombinant human cathepsins C (activated according to
the manufacturer’s instructions) and L were obtained from R&D
Systems (Minneapolis, MN). Cathepsin C was assayed at 251Ci n
25mM MES, pH 6.0, 50mM NaCl, 5mM DTT, 0.1% PEG 3350 using
Gly-Arg-AMC as substrate at 70mM ﬁnal concentration. Cathepsin L
was assayed at 371C in 25mM MES, pH 6.0, 5mM DTT, 0.1% PEG
3350 with Z-Phe-Arg-AMC as substrate (2.4mM ﬁnal concentration)
in a ﬁnal reaction volume of 80ml. Reaction progress was monitored
continuously by product (AMC) ﬂuorescence and initial rates were
obtained by ﬁtting the time courses, including data with substrate
depletion less than 10%. Wild-type cystatin F was pre-activated
with 40mM DTT for 1h. Enzyme concentration was chosen to be
less than the lowest inhibitor concentration used. All measurements
were carried out in at least triplicate. Cathepsin activities in 10mgo f
post-nuclear cell lysates were assayed using 50mM Gly-Phe-AMC
(cathepsin C) or 40mM Z-Phe-Arg-AMC (cathepsin L) in a ﬁnal
volume of 200ml 150mM NaCl, 2mM EDTA, 5mM DTT, 100mM
citrate, pH 5.5. Chymase-dependent CAE activity was measured by
histochemistry using naphthol AS-D CAE substrate and Fast Red
Violet LB staining solution, according to the manufacturer’s
instructions (Sigma-Aldrich Ltd., St Louis, MO) as previously
described (Wolters et al, 2001). Representative images were
collected on a Zeiss LSM510 microscope using an excitation of
540nM. The inherent ﬂuorescent intensity of the CAE-positive cells
were quantitated using Volocity software (Improvision) by dividing
the sum of ﬂuorescence intensity per ﬁeld by the number of cells
within that ﬁeld (n4125 cells).
Metabolic labelling, subcellular fractionation and microscopy
Metabolic labelling experiments were performed essentially as
described previously (Li et al, 2003). Brieﬂy, U937 cells were
preincubated in Met/Cys-free media, labelled for 20min with
[
35S]Met/Cys (Amersham Biosciences) and chased in complete
RPMI medium containing 100mg/ml methionine and 500mg/ml
cysteine. Cystatin F was immunoprecipitated from aliquots of the
cell lysate and medium using 2mg of rabbit serum raised against the
full-length protein. Percoll gradient fractionation of post-nuclear
supernatants was performed essentially as previously reported
(Davidson et al, 1990; West et al, 1994). To improve purity of
lysosomal fractions (Kawashima et al, 1998), 2mM CaCl2 was
added to the post-nuclear supernatant and incubated at 371C for
10min prior to fractionation. Cystatin F, cathepsin C, granzyme A
and markers of the endocytic and secretory pathways were localised
by ﬂuorescence microscopy in BMMC and/or CD8
þ T cells as
detailed in Supplementary data.
Modelling of cathepsin–cystatin complexes
Models for complexes between cystatin F and various cathepsins
were constructed as described previously (Schuettelkopf et al,
2006). In brief, the structure of a cystatin F monomer (from PDB ID:
2CH9) and an appropriate cathepsin structure were superimposed
on their counterparts in the crystallographic complex between steﬁn
B and papain (PDB ID: 1STF) (Stubbs et al, 1990). The resulting
crude model was manually rebuilt to remove clashes where
possible and ﬁnally energy-minimised using GROMACS (Lindahl
et al, 2001) with a simulated annealing protocol. For cathepsin C,
PDB entry 1K3B (Turk et al, 2001) was used.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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